Background: Emodin has anti-neoplastic activities on multiple tumors. However, the molecular mechanisms underlying this effect still remain to be fully understood. Methods: Cell viability and cell cycle distribution were measured using 3-(4, 5-dimethylthiazol-2-yl)-2, and migration were examined by transwell invasion and wound healing assays. Western blot analysis was performed to examine the phosphorylation and protein expression of AMPactivated protein kinase alpha (AMPK ), extracellular signaling-regulated kinase 1/2 (ERK1/2), peroxisome proliferators-activated receptor gamma (PPAR ), insulin-like growth factor (IGF) binding protein 1 (IGFBP1) and the transcription factor Sp1. QRT-PCR was used to examine the mRNA levels of the IGFBP1 gene. Small interfering RNAs (siRNAs) were used to knockdown PPAR and IGFBP1 genes. in vivo. Conclusion: Collectively, our results show that emodin inhibits growth of non-small-cell lung cancer (NSCLC) cells through ERK and AMPKmediated induction of PPAR , followed by reduction of Sp1. This in turn induces IGFBP1 gene expression. Thus, the signaling cascades, positive feedback loop and cooperative interplay between transcription factors-induced the expression of IGFBP1 gene contribute to the overall responses of emodin. This study provides a novel mechanism by which emodin inhibits growth of human lung cancer cells.
Introduction
Lung cancer is the leading cause of cancer-related death worldwide and non-smallcell lung cancer (NSCLC) accounts for approximately 80-85% [1] . Although understand the molecular mechanism and comprehensive treatment have made progress, the 5-year survival rate still remains low, resulting in poor survival [1, 2] . This further emphasizes the need of novel strategies for the prevention and intervention of this malignancy to improve the overall responses and patient survival.
Peroxisome proliferators-activated receptors (PPARs) are members of the nuclear receptor superfamily of ligand-dependent transcription factors, and heterodimerize with retinoid X receptors (RXRs) upon activation and bind to PPAR response element (PPRE) in the , and ).
shown to be expressed in several types of human malignancies, including lung cancer [4, 5] . Large bodies of evidence have demonstrated anti-proliferative and pro-apoptotic effects treatment of cancers [6, 7] . Emodin, a natural anthraquinone derivative isolated from the roots of Rheum palmatuma, exhibited anti-cancer activity through multiple mechanisms in several types of malignancies including lung cancer [8] [9] [10] . Consistent with this, we recently found that emodin inhibited growth of NSCLC cells through AMP-activated protein kinase alpha (AMPK )-and extracellular signaling-regulated kinase (ERK)-mediated inhibition of integrin-linked kinase (ILK) [11] . In addition, one report showed that emodin enhanced chemotherapy-induced cytotoxicity via reducing the expression of excision repair crosscomplementation group 1 (ERCC1) in human lung cancer cells [12] . However, the molecular mechanisms underlying this effect still remain to be fully understood.
The insulin-like growth factor (IGF) binding protein (IGFBP) axis plays critical roles not only in development, metabolism, homeostasis, but also in cell cycle progression, differentiation, apoptosis, and growth in normal and cancer cells [13] . A total of six highprimarily produced by maternal deciduas [15] as well as fetal organs [16] , functions in the pericellular and intracellular compartments to regulate cell growth and survival [14] . In addition to their canonical ligands IGF-I and IGF-II, IGFBP1 correlates with other proteins and plays an important role in apoptosis, growth, angiogenesis, tumor-associated lymphangiogenesis, progression and resistance to treatment in several cancer types [14, 17, 18] . Early studies showed that inhibition of IGF receptor 1 function by an excess of IGFBP1 inhibited growth of breast cancer cells [19] . In addition, conjugation of IGFBP1 with polyethylene glycol suppressed tumor growth in athymic mouse models [20] . The stimulation of growth of acute lymphoblastic leukemia cells by IGF-1 can be partially inhibited by metastatic prostate cancer [23] . Thus, IGFBP1 may have dual effects on cancer cell motility and growth depending upon the content and environment. Data for the link of IGFBP1 and lung cancer risk are sparse, whether the expression and function of IGFBP1 in stimulating or inhibiting lung cancer growth and progression remain elusive. Of note, early study found that IGFBP1 gene was one of primary targets of PPARs [24] .
In this study, we further explored the potential mechanism by which emodin inhibits growth of NSCLC cells. 
Material and Methods

Reagents and cell cultures
Cell viability assay
Cell viability was measured using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay as reported previously [25] . In brief, NSCLC cells were counted and seeded into a 96-well microtiterplate. The cells (5×10 3 to 72 h. Afterwards, 10 Finally, optimal density was determined at 490 nm absorbance using a spectrophotometer (Perkin Elmer, control).
Cell cycle analysis
This procedure was reported previously [26] . In brief, A549 cells were cultured in 6-well culture plates at 3×10 5 or IGFBP1 siRNA, control one for 24 h before treated with emodin for an additional 24 h. Afterwards, the cells were washed and resuspended in PBS for 2 h and incubated in 1 mL of 0.1% sodium citrate containing propidium using the MultiCycle AV DNA Analysis software (Phoenix Flow Systems, USA). The cells were gently washed and treated with emodin, and maintained in serum free medium. Cell migration into the wound surface was monitored by microscopy for up to 24 h. Images of the scratch were taken at expressed as percentage of control (0 h).
Cell invasion assays
Quantitative real-time PCR
primers used in this study were designed as follows: IGFBP1 forward 5'-TCACAGCAGACAGTGTGAGAC transcription using oligo-dT primers and superscript II reverse transcriptase (Invitrogen, Grand Island, NY, conditions were as follows: 10 min at 95 °C, followed by 40 cycles of 15 s at 95 °C, and 1 min at 60°C. Each and standard errors were calculated.
Western blot analysis
lysates were separated on SDS polyacrylamide gels. Membranes (Millipore, MA, USA) were incubated with antibodies against phosphor-ERK and AMPK , PPAR , PPAR , IGFBP1 and Sp1 (1:1000). The membranes were washed and incubated with a secondary antibody raised against rabbit IgG conjugated to horseradish peroxidase (Cell Signaling, Beverly, MA, USA). The membranes were washed again and transferred to freshly the Gel Imagine System (Bio-Rad, Hercules, CA, USA) and documenting the results.
Treatment with PPAR and IGFBP1 siRNAs
The detailed procedure was reported previously [25] . For the transfection procedure, cells were seeded in 6-well or 96-well culture plates in RPMI 1640 medium containing 10% FBS (no antibodies), grown to , IGFBP1 and control siRNAs purchased from Life Technologies (Carlsbad, CA, incubated with Opti-MEM medium (Invitrogen, Carlsbad, CA, USA) up to 10 min, followed by culturing with siRNA (up to 50 nM) for an additional 10 min at room temperature before adding to the cells. After culturing for up to 30 h, the cells were washed and resuspended in fresh media in the presence or absence of emodin for an additional 24 h for all other experiments. Inc., Rockville, MD, USA). Luciferase activity (actual luminescence units) was normalized with SEAP activity within each sample.
Electroporated transfection assays
The detail procedure was reported previously [25] . NSCLC cells (2x10 7 into conical tubes and centrifuged at 1200 rpm for 5 min. After centrifuging, medium was removed and the cells were washed with 1X phosphate buffer saline (PBS), and centrifuged again at 1200 rpm for 5 min. Afterwards, the PBS was aspirated and added Bio-Rad Gene Pulser electroporation buffer. After resuspending the cells, the desired control or IGFBP1 expression vectors (IGFBP1-pCMV6-AC-GFP) purchased from USA) [29] , MX cell plate chamber and closed the lid in Gene Pulser II Electroporation System (Bio-Rad, Hercules, CA, reaching the optimum. After electroporation was completed, the cells were transferred to a tissue culture L electroporation sample to a 6-well tissue culture plate containing 2 mL RPMI1640. Cells were incubated 48 h at 37°C, and then treated with emodin for an additional 24 h.
Xenograft tumors and bioluminescent imaging
The experiments were performed according to the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and approved by the Animal Care and Use Committee of Guangdong Provincial Hospital of Chinese Medicine. A total of 30 eight-week-old female nude mice obtained from Guangdong Provincial Research Center for Laboratory Animal Medicine (Foshan, Guangdong, China) were maintained at the Animal Center of Guangdong Provincial Hospital of carrying luciferase report gene (A549-Luc, obtained from the Guangzhou Land Technology Co., Guangzhou, China) (1x10 6 cells) in 100 L PBS were injected subcutaneously in the upper hind limb of mice. Xenografts were allowed to grow for over one week when the initial measurement was made with calipers. Mice were phase in A549 cells. Moreover, we studied the in vitro invasive properties of lung cancer cells in responding to emodin exposure using matrigel coated transwell inserts. The results indicated that emodin inhibited invasion of A549 cells (Fig. 1B) . In addition, as observed by untreated control cells indicating reduction of migration in A549 and H1975 cells (Fig. 1C) . This result suggested the potential multiple anti-lung cancer effects of emodin.
Emodin increased phosphorylation and protein levels of PPAR , which were abolished by inhibitors of MEK/ERK and AMPK no effect on PPAR protein expression in A549 and H1975 cells ( Fig. 2A) suggesting the and AMPK signaling pathways in NSCLC cells [11] . Herein, we showed that the inhibitors
AMPK
Emodin inhibited NSCLC cell growth and induced cell cycle arrest through activation of PPAR
, we showed that emodin-decreased cell viability and -induced cell cycle arrest were not required in this process (Fig. 3A-B) .
Emodin elevated IGFBP1 protein, mRNA and promoter activity, which was abolished by blockade of PPAR genes [24], in A549 and H1975 cells (Fig. 4A-B) . As expected, emodin also increased IGFBP1 promoter activity, suggesting a transcriptional regulation of this gene (Fig. 4C) . Moreover, gene by siRNAs abolished the effect of emodin on IGFBP1 promoter activity and protein expression (Fig. 4C expression. Notably, ciglitazone, one synthetic PPAR ligand, enhanced the effect of emodin on induction of IGFBP1 protein expression in A549 and H1975 cells (Fig. 4F) suggesting a synergistic effect in this process.
Emodin reduced Sp1 protein expression through PPAR ; exogenous expression of Sp1 diminished the effect of emodin on IGFBP1 expression
protein expression in A549 and H1975 NSCLC cells [11] . Importantly, we found that the emodin-inhibited Sp1 expression was abrogated in cells with silenced PPAR gene (Fig. 5A) . This indicated that expression of PPAR was required in mediating the emodin-reduced Sp1 expression and suggested the role of PPAR activation in this process. Report showed that IGFBP1 promoter contained Sp1 binding sites and that Sp1 could regulate IGFBP1 gene expression and its downstream signaling [31] . Interestingly, we showed that exogenously expression of Sp1 transfected into the cells resisted the effect of emodin on IGFBP1 protein expression (Fig. 5B) , while it had no effect on expression of PPAR (Fig. 5B) . Intriguingly, the effect of Sp1 expression on IGFBP1 was not observed in cells with silenced PPAR gene ( 
com/cpb
interacted with PPAR to regulate the expression of IGFBP1 in NSCLC cells. As expected, ciglitazone increased the effect of emodin on Sp1 protein expression (Fig. 5D ).
While silencing of IGFBP1 attenuated, overexpression of IGFBP1 enhanced emodininduced phosphorylation of AMPK , ERK1/2, and restored the effect of emodin on cell growth inhibition and cell cycle arrest
antagonized the effect of emodin on not only cell growth inhibition but also induction of (Fig. 6D ). This implied a potential feedback regulatory loop of AMPK As expected, overexpression of IGFBP1 had no effect on emodin-reduced Sp1 and induced PPAR protein expression (Fig. 6E ). This suggested that activation of PPAR and inhibition of Sp1 contributed to the emodin-stimulated IGFBP1 expression in this process. 
In vivo
In order to prove the results in vitro, we tested the effect of emodin lung cancer xenografts in nude mice model. Luciferase-expressing A549 cells were injected subcutaneously in nude mice. Mice bearing xenografted lung tumors were treated with control or emodin [30] via intraperitoneal injection for up to 30 days, followed by intraperitoneal injection of D-luciferin. 
Discussion
Growing interest has focused on the use of natural herbs or plants to reduce the incidence and mortality of cancer, leading to encouraging results. Emodin, a bioactive anthraquinone derivative isolated from the rhizomes of Rheum palmatum, has been reported to have various pharmacological functions including anti-cancer activities. Overall, our studies further potential therapeutic modality in several cancers [32, 33] . Although there were important discoveries revealed by previous studies indicated potential multiple signaling pathways and molecular genes or proteins that had been involved in the anti-tumor responses and other functions of emodin [8, 10, 34] , the detailed molecular mechanisms by which this agent in anti-cancer effects still remained to be elucidated. Consistent with our previous study Furthermore, we demonstrated a potential feedback regulation of AMPK by IGFBP1, one of the PPAR targets [24] . The links of AMPK in human hepatoma cells [44] . Also, report showed that activation of AMPK could stimulate IGFBP1 secretion, thereby overcoming the inhibitory effect of insulin in rat hepatoma cells signaling, the possible involvement of other kinase signaling pathways, and up-or downstream mediators underlying this regulation, such as phosphorylation and regulation of IGF-1 receptor [47, 48] , regulation of IGFs [49], forkhead box class O (FOXO) [50] , and hypoxia-inducible factor (HIF) [51] , among others, required to be elucidated in the future studies. In addition to inhibiting IGF effects [52] , IGFBP1 also showed to suppress cancer cell proliferation, invasiveness and 53], which highlighted a tumor suppressor role of IGFBP1. Consistent with these, our results implied that the induction of IGFBP1 expression was required in stimulating the emodininhibited NSCLC growth. However, increased IGFBP1 appeared to be associated with shorter overall survival in men with advanced prostate cancer [23] . Thus, the true functions of IGFBP1 representing a tumor suppressor or oncogene may depend on the capacity of content and environment exposed, which required to be determined. Nevertheless, our study suggested that IGFBP1 may be considered as potential biomarker for lung cancer progression, and that increased IGFBP1 could add compatible with current treatment regimes for lung cancer.
expression. As a common ubiquitous transcription factor that binds to GC-rich motifs of gene promoters, Sp1, with the ability to function as an oncogene or a tumor suppressor depending on the environmental context, was involved in many cellular functions, including differentiation, growth, and apoptosis through regulation of several target genes [54] . One study demonstrated that Sp1-like binding site was responsible for the activation suggested that reduction of Sp1 led to upregulation of IGFBP1 expression by emodin. As the true role of IGFBP1 on lung cancer occurrence and progression have not been well to IGFBP1 promoter) may be involved in the process. Therefore, the potential pathways and mechanisms underlying the reduced-Sp1 protein leading to increase in IGFBP1 expression still remained to be determined with more in depth experiments in the future. Moreover, our additional data implied that the expression of PPAR was required to correlate with Sp1 in axis between PPAR and IGFBP1. Thus, the complicated signaling networks and interactions between transcription factors (e.g., PPAR and Sp1) may control the expression of IGFBP1, this, together with the positive regulatory loop, converged on the overall response of emodin. The interplay of PPAR and Sp1 was reported in other studies. One study showed from cladosporium tenuissimum, through interacting with Sp1, followed by stimulating expression of cyclin-dependent kinase 2) and activator protein 1 (AP-1), could trigger the expression of resistin gene in human monocytic cells [56] . Moreover, one report demonstrated that reduction of Sp1 mediated the anti-tumor effect of emodin and other extracts of polygonum cuspidatum root in oral cancer cells via inhibiting survivin, one of downstream targets of Sp1 [57] . Nevertheless, more Of note, we showed that both PPAR and IGFBP1 expression were involved in the emodin-PPAR may be upstream of IGFBP1 in this process, whether these two signaling pathways (PPAR and IGFBP1) were activated in parallel by emodin, and how they directly converge on emodin-inhibited lung cancer cell growth still remained to be determined. reciprocal interaction between Sp1 and c-Jun proteins contribute to the emodin-inhibited the expression of ILK, which was important in mediating emodin-induced inhibition of lung cancer cell growth [11] . Given the fact that emodin inhibited cancer cell growth through through not only inhibition of ILK but also induction of IGFBP1 gene expression via AMPKthere is a parallel or up-downstream signaling pathway, or potential cross-talk involving in the effect of emodin and which targets (e.g., ILK and IGFBP1 genes) plays a major role required to be determined with more experimental approaches. Alternatively, our results also suggested the possibility of a synergy of emodin and ciglitazone, the enhanced anti-tumor effects of combined emodin and agents, such as several cancer types [40, 58] . Thus, future iterations of this combination may in fact unveiled even greater potency and offered a new strategy in controlling lung cancer growth with less adverse effects. However, more detailed studies are needed to identify insight into the mechanism of synergy between ciglitazone and emodin.
More importantly, our in vivo in vitro, experiments are required to further determine the critical role of IGFBP1 in this process using cells stable transfected with shRNA and exogenously expression vector of IGFBP1 in nude mice model. Of note, emodin has been shown to inhibit tumor metastasis in vivo xenograft tumors required to be determined.
In summary, our results show that emodin inhibits growth of NSCLC cells through activation of PPAR , which is dependent upon activation of AMPK ERK signaling pathways, followed by reduction of Sp1, this leads to induce the expression of IGFBP1 gene. There is a synergy of emodin and ciglitazone. Intriguingly, the interactions between PPAR and Sp1 are required in regulating IGFBP1 expression. Moreover, exogenously expression of IGFBP1 positively feedback strengthens emodin-induced phosphorylation of AMPK expression. Thus, the complex signaling cascades, positive feedback regulatory loops, and cooperative interplay of transcription factors (e.g., PPAR and Sp1)-induced expression of IGFBP1 contribute to the overall responses of emodin (Fig. 7E) . This study unveils a novel mechanism by which emodin inhibits growth of human lung cancer cells. Despite the strong pharmacokinetic studies of emodin are all required in human subjects. Thus, the clinical
